The AHA today submitted a letter to the Office of Science and Technology Policy in response to its request for information on regulatory reform for artificial intelligence, emphasizing the need to reduce regulatory burdens that hinder innovation and increase costs, while ensuring patient safety and data privacy. The letter outlines four key recommendations: synchronizing AI policies with existing frameworks to avoid redundancy, removing regulatory barriers such as fragmented privacy laws and outdated substance use disorder regulations, ensuring safe and effective AI use through clinician involvement in decision loops that impact care delivery and consistent standards for third-party vendors, and addressing organizational and infrastructural challenges by aligning incentives and investing in digital access and literacy. The AHA encourages OSTP to ensure balanced, flexible policies that support innovation and improve care delivery across the health system. 

Headline
The Cybersecurity and Infrastructure Security Agency, National Security Agency and international partners have released guidance on adopting agentic artificial…
Headline
The Food and Drug Administration April 28 announced its plan to advance the implementation of real-time clinical trials, which invite participants to supply…
Headline
The Centers for Medicare & Medicaid Services and the Food and Drug Administration April 23 announced a new pathway to expedite access to certain FDA-…
Headline
Jim VandeHei, CEO of Axios; Marc Boom, M.D., AHA board chair and president and CEO of Houston Methodist; Anne Klibanski, M.D., president and CEO of Mass…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
The Health Sector Coordinating Council’s Cybersecurity Working Group has released a guide on third-party artificial intelligence risk and AI supply…